FDA Grants Orphan Drug Status to Telitacicept for Myasthenia Gravis
RemeGen, a pioneering Chinese biopharmaceutical company, is drawing global attention with the advancement of its novel drug, Telitacicept, in the treatment of generalized myasthenia gravis (gMG). As FDA grants orphan drug status to Telitacicept for myasthenia gravis, this significant regulatory milestone highlights the drug’s potential in addressing a rare, debilitating autoimmune disorder. With promising clinical […]
FDA Grants Orphan Drug Status to Telitacicept for Myasthenia Gravis Read More »